A 12-Week, Open-Label Extension Study For the Treatment of Major Depressive Disorder With Mixed Features.
Phase of Trial: Phase III
Latest Information Update: 10 Apr 2016
At a glance
- Drugs Lurasidone (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions; Registrational
- Acronyms RESOLVE-3
- 01 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Sep 2013 Planned End Date changed from 1 Jul 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.
- 08 Jul 2013 Planned end date changed from 1 Apr 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov.